Breaking News Instant updates and real-time market news.

AMD

AMD

$19.06

-0.03 (-0.16%)

11:39
08/12/18
08/12
11:39
08/12/18
11:39

AMD introduces Radeon Pro WX 8200 at SIGGRAPH 2018

AMD announced a high-performance addition to the Radeon Pro WX workstation graphics lineup with the AMD Radeon Pro WX 8200 graphics card, "delivering the world's best workstation graphics performance for under $1,000 for real-time visualization, virtual reality and photorealistic rendering," the company said. AMD also unveiled major updates to Radeon ProRender and a new alliance with the Vancouver Film School, enabling the next-generation of creators to realize their VFX visions through the power of Radeon Pro graphics. The new turbocharged AMD Radeon Pro WX 8200 graphics card allows professionals to effortlessly accelerate design and rendering. It is the ideal graphics card for design and manufacturing, media and entertainment, and architecture, engineering and construction workloads at all stages of product development. Based on the advanced "Vega" GPU architecture with the 14nm FinFET process, the Radeon Pro WX 8200 graphics card offers the performance required to drive increasingly large and complex models through the entire design visualization pipeline.

  • 28

    Aug

  • 12

    Sep

AMD AMD
$19.06

-0.03 (-0.16%)

08/10/18
GSCO
08/10/18
UPGRADE
Target $21
GSCO
Neutral
AMD upgraded to Neutral from Sell at Goldman Sachs
Goldman Sachs analyst Toshiya Hari upgraded AMD (AMD) to Neutral from Sell and raised his price target for the shares to $21 from $13.25. The chipmaker closed yesterday down 48c to $19.10. Intel's (INTC) struggles with 10nm process technology make it increasingly harder to argue for a bear thesis, even following the recent rally in the shares, Hari tells investors in a research note. The analyst admits, however, that he still has concerns related to AMD's graphics processing unit business given the continued decline in cryptocurrency mining demand and increased competition from Nvidia (NVDA). Nevertheless, the delay in Intel's new products will allow AMD to gain share in not only client computer processing units, but also in the "lucrative" server CPU market, Hari contends. He believes this makes for a balanced risk/reward profile on AMD shares.
08/10/18
GSCO
08/10/18
DOWNGRADE
GSCO
Sell
Intel downgraded to Sell from Neutral at Goldman Sachs
Goldman Sachs analyst Toshiya Hari downgraded Intel (INTC) to Sell from Neutral and lowered his price target for the shares to $44 from $49. The chipmaker closed yesterday up 18c to $50.14. Hari coupled the downgrade with an upgrade of AMD (AMD) to Neutral from Sell. Intel's struggles with 10nm process technology makes the analyst incrementally more negative on the company's competitive positioning and margin outlook. He expects a worsening product mix in the near-term, ramp in 10nm costs and growing depreciation to drive margin pressure and Intel's earnings below consensus expectations. Hari sees downside risk in the shares.
08/10/18
08/10/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. AMD (AMD) upgraded to Neutral from Sell at Goldman Sachs with analyst Toshiya Hari saying Intel's (INTC) struggles with 10nm process technology make it increasingly harder to argue for a bear thesis, even following the recent rally in the shares. 2. RBS (RBS) upgraded to Buy from Neutral at UBS with analyst Jason Napier saying the bank's capital strength is being undervalued by the market. 3. Dropbox (DBX) upgraded to Outperform from Sector Perform at RBC Capital with analyst Mark Mahaney citing "strong" Q2 results and above consensus guidance. 4. Sanofi (SNY) upgraded to Buy from Neutral at Citi. 5. Floor & Decor (FND) upgraded to Outperform from Market Perform at Wells Fargo with analyst Zachary Fadem saying he believes current share levels represent a "compelling long-term entry point for one of the best growth stories in all of retail." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/10/18
08/10/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. GOLDMAN CUTS INTEL, UPGRADES AMD: Goldman Sachs analyst Toshiya Hari downgraded Intel (INTC) to Sell from Neutral and lowered his price target for the shares to $44 from $49. Hari coupled the downgrade with an upgrade of AMD (AMD) to Neutral from Sell. Intel's struggles with 10nm process technology made the analyst incrementally more negative on the company's competitive positioning and margin outlook. He expects a worsening product mix in the near-term, ramp in 10nm costs and growing depreciation to drive margin pressure and Intel's earnings below consensus expectations. The delay in Intel's new products will allow AMD to gain share in not only client computer processing units, and also in the "lucrative" server CPU market, Hari contended. He believes this makes for a balanced risk/reward profile on AMD shares. In late morning trading, Intel is down 2.5% and AMD is up fractionally. BOOKING HOLDINGS DOWNGRADED AT MULTIPLE FIRMS: UBS analyst Eric Sheridan downgraded Booking Holdings (BKNG) to Neutral from Buy and lowered his price target for the shares to $2,060 from $2,320 following the company's Q2 results. JPMorgan analyst Doug Anmuth downgraded Booking Holdings to Neutral from Overweight and lowered his price target for the shares to $2,070 from $2,385. Additionally, Citi analyst Mark May downgraded Booking Holdings to Neutral from Buy and lowered his price target for the shares to $2,150 from $2,350. Booking Holding is down over 2% in late morning trading. JPMORGAN CUTS CAMPBELL SOUP TO UNDERWEIGHT: JPMorgan analyst Ken Goldman downgraded Campbell Soup (CPB) to Underweight from Neutral with a $36 price target, saying he believes a sale of the company at a significant premium is unlikely. Campbell Soup is down over 2% in late morning trading. CANTOR SEES MANY REASONS FOR UNITEDHEALTH ACQUIRING ATHENAHEALTH: Numerous media sources cited a Dealreporter story indicating that UnitedHealth (UNH) is now in the second round of bidding for Athenahealth (ATHN), Cantor Fitzgerald analyst Steven Halper said in a research note. There are "many reasons" why UnitedHealth's Optum would benefit from the acquisition of Athenahealth, the analyst contended. With or without the deal, the analyst expects UnitedHealth will deploy capital and grow its various Optum businesses over time. He reiterated an Overweight rating on shares with a $300 price target.

TODAY'S FREE FLY STORIES

CBFV

CB Financial Services

$25.79

(0.00%)

14:42
11/21/18
11/21
14:42
11/21/18
14:42
Hot Stocks
CB Financial Services increases dividend by 4.5% to 23c per share »

CB Financial Services,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BECN

Beacon Roofing

$32.94

4.87 (17.35%)

14:28
11/21/18
11/21
14:28
11/21/18
14:28
Hot Stocks
CD&R Group to buy additional shares in Beacon Roofing »

In a regulatory filing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

NTN

NTN Buzztime

$2.70

-0.1 (-3.57%)

14:26
11/21/18
11/21
14:26
11/21/18
14:26
Hot Stocks
Northstar reports 10.33% stake in NTN Buzztime »

On November 21, Northstar…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:23
11/21/18
11/21
14:23
11/21/18
14:23
Conference/Events
The U.S. Commodity Futures Trading Commission to hold a podcast »

The Commodity Futures…

RHHBY

Roche

$0.00

(0.00%)

, ABBV

AbbVie

$85.75

-2.35 (-2.67%)

14:18
11/21/18
11/21
14:18
11/21/18
14:18
Hot Stocks
Roche announces FDA grants accelerated approval for Venclexta combo »

Roche (RHHBY) announced…

RHHBY

Roche

$0.00

(0.00%)

ABBV

AbbVie

$85.75

-2.35 (-2.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Dec

  • 03

    Dec

  • 24

    Dec

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
11/21/18
11/21
14:17
11/21/18
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABBV

AbbVie

$85.70

-2.4 (-2.72%)

, RHHBY

Roche

$0.00

(0.00%)

14:16
11/21/18
11/21
14:16
11/21/18
14:16
Hot Stocks
AbbVie says FDA grants accelerated approval to Venclexta-azacitidine combo »

AbbVie (ABBV) announced…

ABBV

AbbVie

$85.70

-2.4 (-2.72%)

RHHBY

Roche

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Dec

  • 03

    Dec

  • 24

    Dec

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
11/21/18
11/21
14:16
11/21/18
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WPP

WPP

$54.99

1.4 (2.61%)

14:15
11/21/18
11/21
14:15
11/21/18
14:15
Periodicals
Martin Sorrell to poach senior executive from WPP, Sky News reports »

Martin Sorrell is to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

TGT

Target

$69.10

0.05 (0.07%)

14:10
11/21/18
11/21
14:10
11/21/18
14:10
Options
Target calls lead puts 3:1 after a big drop in shares »

Target calls lead puts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

HWBK

Hawthorn Bancshares

$22.71

(0.00%)

14:08
11/21/18
11/21
14:08
11/21/18
14:08
Hot Stocks
Ategra stake in Hawthorn Bancshares falls to 4.97% »

As of November 20, Ategra…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IAM

I-AM Capital

$10.00

(0.00%)

14:04
11/21/18
11/21
14:04
11/21/18
14:04
Hot Stocks
I-AM Capital announces closing of transaction with SMAAASH Entertainment »

Smaaash Entertainment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBD

Banco Bradesco

$9.60

0.23 (2.45%)

14:00
11/21/18
11/21
14:00
11/21/18
14:00
Options
Longer-term put buyer in Banco Bradesco »

Longer-term put buyer in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

SPY

SPDR S&P 500 ETF Trust

$266.76

2.64 (1.00%)

, SPX

S&P 500

$0.00

(0.00%)

13:56
11/21/18
11/21
13:56
11/21/18
13:56
Periodicals
Hedge funds get battered in October and are down for year, CNBC says »

According to a CNBC…

SPY

SPDR S&P 500 ETF Trust

$266.76

2.64 (1.00%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIPS

Vipshop

$5.54

0.07 (1.28%)

13:50
11/21/18
11/21
13:50
11/21/18
13:50
Options
Aggressive call buy in Vipshop »

Aggressive call buy in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

13:50
11/21/18
11/21
13:50
11/21/18
13:50
General news
Treasury Action: yields remain only marginally firmer »

Treasury Action: yields…

PFE

Pfizer

$43.23

-0.3 (-0.69%)

13:41
11/21/18
11/21
13:41
11/21/18
13:41
Hot Stocks
Pfizer says FDA approves DAURISMO for adults with newly-diagnosed AML »

Pfizer announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 03

    Dec

  • 10

    Dec

EFA

iShares MSCI EAFE Index Fund

$62.35

1.05 (1.71%)

13:40
11/21/18
11/21
13:40
11/21/18
13:40
Options
Call buying in iShares Emerging Markets Fund and iShares MSCI EAFA Fund »

Call buying in iShares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

13:30
11/21/18
11/21
13:30
11/21/18
13:30
Options
Vix calls lead puts 4:1 as the index drops 9% »

Vix calls lead puts 4:1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKRX

Akorn

$6.95

0.18 (2.66%)

13:25
11/21/18
11/21
13:25
11/21/18
13:25
Options
Akorn call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

OMED

OncoMed

$1.37

(0.00%)

13:22
11/21/18
11/21
13:22
11/21/18
13:22
Hot Stocks
OncoMed awarded European patent for method for making heteromultimeric molecules 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AQST

Aquestive Therapeutics

$10.12

-3.05 (-23.16%)

, RDY

Dr. Reddy's

$36.37

-0.11 (-0.30%)

13:17
11/21/18
11/21
13:17
11/21/18
13:17
Hot Stocks
Aquestive under pressure after generic Suboxone patent decision »

Shares of Aquestive…

AQST

Aquestive Therapeutics

$10.12

-3.05 (-23.16%)

RDY

Dr. Reddy's

$36.37

-0.11 (-0.30%)

MYL

Mylan

$33.29

-0.65 (-1.92%)

ENDP

Endo

$12.39

-0.14 (-1.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 02

    Dec

  • 04

    Dec

  • 19

    Jan

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
11/21/18
11/21
13:17
11/21/18
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
11/21/18
11/21
13:16
11/21/18
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GME

GameStop

$12.60

0.3 (2.44%)

, T

AT&T

$30.01

0.6 (2.04%)

13:15
11/21/18
11/21
13:15
11/21/18
13:15
Hot Stocks
GameStop jumps over 10% after agreeing to sell Spring Mobile unit »

Shares of GameStop (GME)…

GME

GameStop

$12.60

0.3 (2.44%)

T

AT&T

$30.01

0.6 (2.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 29

    Nov

  • 29

    Nov

  • 03

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.